Serenity Medical Reports Long-Term River Stent Success in IIH
Maple Grove, Minn., July 22, 2026 Serenity Medical announced new four- to five-year clinical data demonstrating the long-term effectiveness...
Quality of Life
Advertisement
Teva Presents New AUSTEDO Data Supporting Sustained TD Treatment
PARSIPPANY, New Jersey, USA & TEL AVIV, Israel – June 8, 2026 Teva Pharmaceuticals has unveiled new real-world and...
Teva Reports Real-World Benefits of AUSTEDO for Huntington’s Disease Chorea
PARSIPPANY, N.J. and TEL AVIV, Israel, June 5, 2026 Teva Pharmaceuticals announced new real-world data demonstrating that treatment with...
Jazz Highlights New Xywav Data Across Narcolepsy and Idiopathic Hypersomnia
DUBLIN, Ireland, June 4, 2026 Jazz Pharmaceuticals has announced the presentation of an extensive portfolio of new clinical and...
Teva Reports New AUSTEDO Data in Huntington’s Chorea
PARSIPPANY, N.J. and TEL AVIV, Israel, June 5, 2026 Teva Pharmaceuticals has presented new real-world evidence demonstrating that treatment...
Advertisements
Privo Technologies Completes Phase 2 Run-In for PRV111 Oral Cancer Patch
PEABODY, Mass., Oct. 14, 2025 — Privo Technologies, Inc., a clinical-stage biopharmaceutical company pioneering localized cancer therapies, announced the...
Sanofi’s Wayrilz Approved in the U.S. as First BTK Inhibitor for Immune Thrombocytopenia
Sanofi has secured U.S. FDA approval for Wayrilz (rilzabrutinib), marking the first Bruton’s tyrosine kinase (BTK) inhibitor approved for...
Advertisement
